Nexture Bio Introduces the Doselet™, a Needle-Free Daily Alternative to NAD+ Injections
Clinical Early Access Program opens to wellness clinics and practitioners ahead of public launch
VACAVILLE, Calif. — July 31, 2026 — Nexture Bio has launched its NAD+ Doselet Clinical Early Access Program, inviting clinician-led wellness practices to be the first to offer the NAD+ Doselet ahead of its public market launch.
The NAD+ Doselet is a centimeter-sized, plant-based nanofiber patch applied to the inside of the cheek that absorbs gradually. Each Doselet is formulated to deliver 10 mg of NAD+ over about 10 to 15 minutes. Sold in 30-unit packs, Doselets are designed as a patient-friendly daily NAD+ format.
An NAD+ Doselet from Nexture Bio rests on a fingertip, illustrating the patch’s actual size.
“For the first time, wellness clinics and practitioners can offer a NAD+ format that fits perfectly into everyday wellness rituals in between visits, or for patients who don't want an injection,” said Teryn Wolfe, founder and CEO of Nexture Bio.
The Clinical Early Access Program onboards wellness and medical professionals, offering exclusive access to first batches, alongside product education, patient-facing FAQs and early launch updates before the broader market.
“We're hand-selecting clinics whose patient mix aligns with the platform, so the first practices to carry the Doselet help shape how we scale — not just for NAD+, but across the pipeline,” Wolfe added.
Doselets NAD+, a daily supplement designed to support cellular energy and metabolism, are sold in 3-count boxes of 10-milligram doses.
The buccal nanofiber platform is a delivery technology first, with NAD+ as the lead indication. Nexture Bio is developing additional actives for the format and plans to pursue licensing partnerships with compounding pharmacies, telehealth clinics and longevity practices.
Wellness clinics and practitioners ready to be first can apply at doselets.com/early-access.html.
About Nexture Bio
Nexture Bio is a nanofiber delivery platform company solving nutraceuticals’ most persistent problem: getting bioactives into the body intact. The platform is designed to give clinicians a consistent, repeatable dosing format — the same precision they expect from injectables, without the injection. The company's first product, the Doselet, brings this technology to wellness clinics and practitioners as a daily NAD+ format. Learn more at doselets.com.
Teryn Wolfe, founder and CEO of Nexture Bio, reviews Doselet production with her lab team ahead of the Clinical Early Access Program launch.
About Doselets
Each centimeter-sized, plant-based Doselet adheres to the inner cheek and is formulated to deliver 10 mg of NAD+ in minutes. The Doselet is designed to fit into the routines clinics and patients already have.
Learn more and apply for early access at doselets.com.
Media Contact
Teryn Wolfe, founder and CEO
hello@doselets.com
https://www.doselets.com
All images courtesy Nexture Bio
